Moraima Jimenez
Overview
Explore the profile of Moraima Jimenez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
218
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Serna A, Navarro V, Iacoboni G, Lopez L, Sancho J, Gonzalez-Barca E, et al.
Haematologica
. 2024 Jul;
110(1):173-178.
PMID: 38988269
No abstract available.
2.
Lahmer T, Salmanton-Garcia J, Marchesi F, El-Ashwah S, Nucci M, Besson C, et al.
Infection
. 2024 May;
52(3):1191-1194.
PMID: 38771466
No abstract available.
3.
Aiello T, Salmanton-Garcia J, Marchesi F, Weinbergerova B, Glenthoj A, van Praet J, et al.
Haematologica
. 2024 Apr;
109(8):2693-2700.
PMID: 38572549
No abstract available.
4.
Salmanton-Garcia J, Marchesi F, Farina F, Weinbergerova B, Itri F, Davila-Valls J, et al.
EClinicalMedicine
. 2024 Mar;
71:102553.
PMID: 38533127
Background: The COVID-19 pandemic heightened risks for individuals with hematological malignancies due to compromised immune systems, leading to more severe outcomes and increased mortality. While interventions like vaccines, targeted antivirals,...
5.
Lahmer T, Salmanton-Garcia J, Marchesi F, El-Ashwah S, Nucci M, Besson C, et al.
Infection
. 2024 Feb;
52(3):1125-1141.
PMID: 38388854
No abstract available.
6.
Mingot-Castellano M, Garcia-Candel F, Martinez-Nieto J, Garcia-Arroba J, de la Rubia-Comos J, Gomez-Segui I, et al.
Blood
. 2024 Jan;
143(18):1807-1815.
PMID: 38237147
Caplacizumab prevents the interaction between von Willebrand factor and platelets and is used to treat immune thrombotic thrombocytopenic purpura (iTTP). Its administration has been associated with a delay in ADAMTS13...
7.
Musto P, Salmanton-Garcia J, Sgherza N, Bergantim R, Farina F, Glenthoj A, et al.
Hematol Oncol
. 2023 Dec;
42(1):e3240.
PMID: 38050405
Patients affected by multiple myeloma (MM) have an increased risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection and subsequent coronavirus (20)19 disease (COVID-19)-related death. The changing epidemiological...
8.
Rossi G, Salmanton-Garcia J, Cattaneo C, Marchesi F, Davila-Valls J, Martin-Perez S, et al.
Int J Infect Dis
. 2023 Oct;
137:98-110.
PMID: 37863310
Objectives: Elderly patients with hematologic malignancies face the highest risk of severe COVID-19 outcomes. The infection's impact on different age groups remains unstudied in detail. Methods: We analyzed elderly patients...
9.
Jimenez M, Fernandez-Naval C, Navarro V, Novoa S, Martinez-Gallo M, Medina D, et al.
Am J Hematol
. 2023 May;
98(8):1204-1213.
PMID: 37151135
Data on the effect of booster SARS-CoV-2 vaccination are mainly focused on humoral immunogenicity, while the kinetics of vaccine-induced cellular response and its correlation with effectiveness in hematologic patients are...
10.
van Doesum J, Salmanton-Garcia J, Marchesi F, Di Blasi R, Falces-Romero I, Cabirta A, et al.
Blood Adv
. 2023 Apr;
7(11):2645-2655.
PMID: 37058479
Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great impact and has previously been shown...